GO:0004163 diphosphomevalonate decarboxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004163 (diphosphomevalonate decarboxylase activity) catalyzes the ATP-dependent conversion of (R)-5-diphosphomevalonate to isopentenyl diphosphate, CO2, ADP, H+ and phosphate, the final step of the classical mevalonate pathway.
• The enzyme is a member of the GHMP kinase superfamily and uses a conserved aspartate to abstract the C3 hydroxyl proton, triggering decarboxylation and dehydration.
• A single amino acid mutation can switch the enzyme from a decarboxylase into a kinase, demonstrating the mechanistic plasticity of the active site.
• In archaea such as Sulfolobus solfataricus and Aeropyrum pernix, modified mevalonate pathways use alternative enzymes and intermediates, highlighting evolutionary diversity.
• Diphosphomevalonate decarboxylase activity is essential for isoprenoid biosynthesis, affecting cholesterol, dolichol, ubiquinone, and prenylated protein production.
• Dysregulation of the mevalonate pathway is linked to cancer, cardiovascular disease, and myelination disorders, making this enzyme a potential therapeutic target.
Description
Diphosphomevalonate decarboxylase (DPMD) activity, encoded by the GO term GO:0004163, is the terminal enzymatic step of the classical mevalonate (MVA) pathway. It catalyzes the ATP-dependent decarboxylation and dehydration of (R)-5-diphosphomevalonate to yield isopentenyl diphosphate (IPP), the universal precursor of all isoprenoids. This reaction is essential for the biosynthesis of cholesterol, steroid hormones, dolichols, ubiquinone, and prenylated proteins, and thus for cell membrane integrity, signaling, and energy metabolism. Because IPP is a central metabolite, DPMD activity is tightly regulated and has been studied in organisms ranging from humans to hyperthermophilic archaea. Structural and mechanistic studies have revealed that DPMD belongs to the GHMP kinase superfamily and uses a conserved aspartate residue to initiate catalysis. Mutational analyses have shown that a single amino acid substitution can convert the decarboxylase into a kinase, providing insights into enzyme evolution and catalytic promiscuity. In this article, we provide a comprehensive overview of GO:0004163, covering its definition, mechanism, key genes, disease associations, and experimental models. We also highlight how CRISPR-based approaches can be used to dissect the function of DPMD and its role in health and disease.
diphosphomevalonate decarboxylase activity At A Glance
| GO ID | GO:0004163 |
|---|---|
| GO term | diphosphomevalonate decarboxylase activity |
| Ontology | molecular_function |
| Synonym | mevalonate diphosphate decarboxylase activity; pyrophosphomevalonate decarboxylase activity; ATP:(R)-5-diphosphomevalonate carboxy-lyase (dehydrating) |
| Major function | Catalyzes the final step of the mevalonate pathway, producing isopentenyl diphosphate |
| Reaction | (R)-5-diphosphomevalonate + ATP = ADP + CO2 + H+ + isopentenyl diphosphate + phosphate |
| Enzyme family | GHMP kinase superfamily |
| Cofactor | ATP (required for phosphorylation and decarboxylation) |
| Pathway | Mevalonate pathway (isoprenoid biosynthesis) |
What Is GO:0004163?
Diphosphomevalonate decarboxylase activity (GO:0004163) is defined as the catalysis of the reaction: (R)-5-diphosphomevalonate + ATP = ADP + CO2 + H+ + isopentenyl diphosphate + phosphate. In other words, it is the enzyme activity that removes a carboxyl group from (R)-5-diphosphomevalonate and dehydrates the intermediate, using ATP as a phosphoryl donor, to produce isopentenyl diphosphate, the building block for all isoprenoids.
Why Is diphosphomevalonate decarboxylase activity Important in Cell Biology?
Diphosphomevalonate decarboxylase activity is critical for the mevalonate pathway, which supplies isopentenyl diphosphate for the synthesis of cholesterol, heme A, ubiquinone, dolichol, and prenylated proteins. Dysregulation of this pathway is implicated in cardiovascular disease, cancer, and neurological disorders. Understanding the enzyme's mechanism and regulation can inform the development of therapeutics targeting the mevalonate pathway, such as statins and bisphosphonates.
• Provides isopentenyl diphosphate, the universal precursor for all isoprenoids.
• Essential for cholesterol biosynthesis and membrane integrity.
• Required for prenylation of small GTPases, which are key signaling molecules.
• Plays a role in myelination, as pyrophosphomevalonate decarboxylase activity changes during myelination.
• Target of statins and bisphosphonates, which modulate the mevalonate pathway.
• Enzyme mechanism involves a unique ATP-dependent decarboxylation, making it a model for studying GHMP kinases.
• Single amino acid mutations can alter substrate specificity, offering insights into enzyme evolution.
• Archaeal homologs reveal alternative mevalonate pathways and thermostability mechanisms.
What Happens During diphosphomevalonate decarboxylase activity?
Substrate binding and ATP-dependent phosphorylation
In simple terms: The enzyme grabs its substrate and uses ATP to add a phosphate group, setting up the reaction.
Diphosphomevalonate decarboxylase binds (R)-5-diphosphomevalonate and ATP in a sequential manner. The enzyme belongs to the GHMP kinase superfamily and uses a conserved aspartate residue to abstract the C3 hydroxyl proton of the substrate, facilitating phosphorylation by ATP. This step is essential for the subsequent decarboxylation and dehydration.
Decarboxylation and dehydration
In simple terms: After phosphorylation, the enzyme removes a carboxyl group and a water molecule to form the final product.
Following phosphorylation, the intermediate undergoes decarboxylation, releasing CO2, and dehydration, resulting in the formation of isopentenyl diphosphate. The reaction is coupled to ATP hydrolysis, producing ADP and inorganic phosphate. The mechanism involves a transient carbocation intermediate stabilized by the enzyme's active site residues.
Product release and enzyme turnover
In simple terms: The enzyme releases the product and resets for another round.
Isopentenyl diphosphate, ADP, CO2, H+, and phosphate are released from the active site. The enzyme undergoes conformational changes to reset for the next catalytic cycle. Structural studies have revealed that the enzyme exists as a dimer or tetramer, and oligomerization may influence catalytic efficiency.
Evolutionary variations in archaea
In simple terms: Some archaea use slightly different enzymes or pathways to make the same product.
In hyperthermophilic archaea such as Sulfolobus solfataricus, the enzyme forms a disulfide bond that enhances thermostability. In Aeropyrum pernix, a modified mevalonate pathway proceeds via trans-anhydromevalonate 5-phosphate, bypassing the classical diphosphomevalonate decarboxylase step. These variations highlight the evolutionary adaptability of isoprenoid biosynthesis.
Key Genes Involved in GO:0004163 diphosphomevalonate decarboxylase activity
The following genes and proteins are directly or indirectly involved in diphosphomevalonate decarboxylase activity and the mevalonate pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MVD | Encodes diphosphomevalonate decarboxylase in humans | Target for cholesterol-lowering drugs; mutations linked to metabolic disorders |
| MVK | Mevalonate kinase, phosphorylates mevalonate | Deficiency causes mevalonic aciduria and hyper-IgD syndrome |
| PMVK | Phosphomevalonate kinase, converts mevalonate-5-phosphate to diphosphomevalonate | Essential for mevalonate pathway flux |
| FDPS | Farnesyl diphosphate synthase, condenses IPP with DMAPP | Target of bisphosphonates |
| HMGCR | HMG-CoA reductase, rate-limiting enzyme of mevalonate pathway | Target of statins |
| GGPS1 | Geranylgeranyl diphosphate synthase | Involved in protein prenylation |
| IDI1 | Isopentenyl diphosphate isomerase, converts IPP to DMAPP | Balances isoprenoid precursors |
| SQS | Squalene synthase, first committed step to sterol synthesis | Target for cholesterol management |
| Sulfolobus solfataricus DPMD | Archaeal homolog with disulfide bond for thermostability | Model for protein stability studies |
| Aeropyrum pernix DPMD | Archaeal enzyme in modified mevalonate pathway | Model for pathway evolution |
| Streptococcus pneumoniae DPMD | Bacterial homolog | Antibiotic target research |
| Human DPMD mutants | Engineered variants with altered activity | Mechanistic studies and drug screening |
| DPMD from Trypanosoma | Parasite enzyme | Potential drug target for neglected diseases |
| Plant DPMD | Involved in plant isoprenoid biosynthesis | Herbicide and biofuel research |
| Yeast ERG19 | Yeast diphosphomevalonate decarboxylase | Model for genetic and biochemical studies |
| Archaeal DPMD variants | Thermostable enzymes | Biotechnological applications |
How Is diphosphomevalonate decarboxylase activity Regulated?
Diphosphomevalonate decarboxylase activity is regulated at multiple levels. In humans, the MVD gene is transcriptionally regulated by sterol regulatory element-binding proteins (SREBPs) in response to cellular cholesterol levels. The enzyme's activity can also be modulated by feedback inhibition from downstream metabolites such as farnesyl diphosphate and geranylgeranyl diphosphate. Post-translational modifications, including phosphorylation, may affect enzyme stability and localization. In archaea, disulfide bond formation enhances thermostability and activity under extreme conditions.
diphosphomevalonate decarboxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MVD | Mevalonic aciduria; hyper-IgD syndrome | Knockout mice; patient-derived fibroblasts |
| MVK | Mevalonic aciduria; hyper-IgD syndrome | Knock-in mouse models; iPSC-derived macrophages |
| HMGCR | Cardiovascular disease; statin response | Liver-specific knockout mice; hepatocyte cell lines |
| FDPS | Bone diseases; cancer | Osteoclast cultures; xenograft models |
| IDI1 | Metabolic disorders | Zebrafish models; CRISPR knockout cell lines |
Mevalonate pathway disorders
Deficiencies in mevalonate pathway enzymes, including mevalonate kinase and diphosphomevalonate decarboxylase, can lead to rare metabolic disorders such as mevalonic aciduria and hyper-IgD syndrome. These conditions are characterized by recurrent fevers, developmental delay, and elevated levels of mevalonate metabolites.
Cancer
The mevalonate pathway is often upregulated in cancer cells to support rapid proliferation and survival. Diphosphomevalonate decarboxylase activity contributes to the production of isoprenoids needed for oncogenic signaling. Inhibitors of the pathway, such as statins, have shown potential in cancer therapy.
Neurodegeneration and myelination
Changes in pyrophosphomevalonate decarboxylase activity have been observed during myelination, suggesting a role in myelin formation and maintenance. Dysregulation of cholesterol synthesis is implicated in neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
From diphosphomevalonate decarboxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of MVD knockout on cholesterol synthesis? | MVD knockout HeLa or HepG2 cells |
| How does a point mutation in the active site affect enzyme kinetics? | Point-mutant MVD expressed in E. coli or mammalian cells |
| Can we rescue mevalonate pathway defects with wild-type MVD? | Knock-in of wild-type MVD into mutant cells |
| Where is MVD localized in the cell? | Tagged knock-in of MVD with GFP or FLAG |
| What is the effect of MVD overexpression on cell proliferation? | Overexpression of MVD in cancer cell lines |
| How does MVD interact with other pathway enzymes? | Co-immunoprecipitation and proximity labeling |
How to Study the diphosphomevalonate decarboxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | DPMD activity | Drug screening; kinetic studies |
| X-ray crystallography | 3D structure | Mechanistic insights; drug design |
| Site-directed mutagenesis | Effect of mutations on activity | Identifying catalytic residues |
| CRISPR knockout | Loss-of-function phenotypes | Pathway analysis; drug sensitivity |
| RNA-seq | Transcriptional changes | Pathway regulation studies |
| Proteomics | Protein expression and modifications | Post-translational regulation |
| Metabolomics | Metabolite levels | Flux analysis |
| Thermal shift assay | Protein stability | Buffer optimization; ligand binding |
Enzymatic assays
Diphosphomevalonate decarboxylase activity can be measured using coupled enzymatic assays that monitor NADH oxidation or ATP consumption. Radioactive assays with 14C-labeled substrate are also used to quantify product formation.
Structural biology
X-ray crystallography and cryo-electron microscopy have been used to determine the structure of DPMD from various organisms, revealing the active site architecture and conformational changes during catalysis.
Mutagenesis and kinetic analysis
Site-directed mutagenesis of conserved residues, followed by kinetic analysis, has identified key catalytic residues and elucidated the reaction mechanism.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to mevalonate pathway inhibitors, revealing synthetic lethal interactions with DPMD.
How CRISPR Can Be Used to Study GO:0004163 diphosphomevalonate decarboxylase activity
Knockout
CRISPR-Cas9 knockout of MVD or other mevalonate pathway genes can be used to study the consequences of loss of diphosphomevalonate decarboxylase activity on cell growth, cholesterol synthesis, and sensitivity to statins. Knockout cell lines are valuable for identifying compensatory pathways and synthetic lethal interactions.
Point Mutation
Introducing point mutations into the MVD gene via CRISPR base editing or homology-directed repair allows researchers to dissect the catalytic mechanism and test the effect of specific residues on enzyme activity. For example, mutation of the conserved aspartate can abolish decarboxylase activity.
Knock-in
Knock-in of tagged MVD (e.g., GFP or FLAG) enables visualization of protein localization and interaction partners. Knock-in of disease-associated mutations can create isogenic models for studying mevalonate pathway disorders.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of MVD can be used to study the effects of increased diphosphomevalonate decarboxylase activity on cell proliferation, lipid metabolism, and drug resistance.
How EDITGENE Supports diphosphomevalonate decarboxylase activity Research
Researchers studying diphosphomevalonate decarboxylase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cholesterol synthesis, drug response, or cancer cell growth. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic modifications in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for diphosphomevalonate decarboxylase activity research.
Frequently Asked Questions About diphosphomevalonate decarboxylase activity
What is diphosphomevalonate decarboxylase activity?
It is the enzyme activity that catalyzes the final step of the mevalonate pathway, converting (R)-5-diphosphomevalonate to isopentenyl diphosphate using ATP.
What genes are involved in diphosphomevalonate decarboxylase activity?
The primary gene is MVD, which encodes the enzyme. Other mevalonate pathway genes include MVK, PMVK, and FDPS.
What is the role of GO:0004163 in cholesterol synthesis?
It produces isopentenyl diphosphate, a precursor for cholesterol and other isoprenoids.
How is diphosphomevalonate decarboxylase regulated?
It is regulated by SREBPs at the transcriptional level and by feedback inhibition from downstream metabolites.
What diseases are associated with diphosphomevalonate decarboxylase deficiency?
Deficiency is linked to mevalonic aciduria and hyper-IgD syndrome, though MVD mutations are rare.
Can CRISPR be used to study diphosphomevalonate decarboxylase?
Yes, CRISPR knockout, knock-in, and point mutations are powerful tools to dissect its function.
What is the mechanism of diphosphomevalonate decarboxylase?
It uses a conserved aspartate to abstract a proton, followed by ATP-dependent phosphorylation, decarboxylation, and dehydration.
Are there archaeal homologs of diphosphomevalonate decarboxylase?
Yes, archaea such as Sulfolobus solfataricus have thermostable homologs with a disulfide bond.
What is the difference between MVD and MVK?
MVD encodes diphosphomevalonate decarboxylase, while MVK encodes mevalonate kinase, which phosphorylates mevalonate.
How can I measure diphosphomevalonate decarboxylase activity?
Enzymatic assays using radiolabeled substrate or coupled NADH oxidation are commonly used.
Conclusion
Diphosphomevalonate decarboxylase activity (GO:0004163) is a critical enzymatic step in the mevalonate pathway, responsible for producing isopentenyl diphosphate, the building block of all isoprenoids. Its mechanism, regulation, and role in disease have been extensively studied, and CRISPR-based tools now enable precise functional interrogation. Understanding this enzyme offers opportunities for therapeutic intervention in cancer, cardiovascular disease, and metabolic disorders.
References
- 1. Motoyama K et al.. 2017. A Single Amino Acid Mutation Converts (R)-5-Diphosphomevalonate Decarboxylase into a Kinase.. J Biol Chem 292(6):2457-2469 PMID: 28003359
- 2. Hattori A et al.. 2015. In Vivo Formation of the Protein Disulfide Bond That Enhances the Thermostability of Diphosphomevalonate Decarboxylase, an Intracellular Enzyme from the Hyperthermophilic Archaeon Sulfolobus solfataricus.. J Bacteriol 197(21):3463-71 PMID: 26303832
- 3. Hayakawa H et al.. 2018. Modified mevalonate pathway of the archaeon Aeropyrum pernix proceeds via trans-anhydromevalonate 5-phosphate.. Proc Natl Acad Sci U S A 115(40):10034-10039 PMID: 30224495
- 7. Chen CL et al.. 2020. Visualizing the enzyme mechanism of mevalonate diphosphate decarboxylase.. Nat Commun 11(1):3969 PMID: 32769976
- 8. Marco C et al.. 1983. Relationship between changes in free cholesterol and pyrophosphomevalonate decarboxylase activity during myelination.. Neurochem Res 8(6):711-21 PMID: 6621770
